Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Of all the markets we track, the US pays the steepest price for Rifaximin, and 2025 only stretched that lead. American material began the year near USD 1,090,000/MT and worked its way up to roughly USD 1,155,000/MT by Q4, a gain of about 6.0%. Demand carried most of the load, with feedstock not far behind. The global average kept pace, moving from USD 940,000/MT in early 2025 to USD 995,000/MT by December, then on to USD 1,035,000/MT in Q2 2026. This has been a slow grind higher, not a spike.
Rifaximin (CAS 80621-81-4) is a semi-synthetic rifamycin that hardly leaves the gut, doing its work locally by shutting down bacterial RNA polymerase. Making it means several semi-synthesis steps off rifamycin O, or rifamycin SV, both of which come out of fermentation. The demand sits in gut and liver medicine: traveller's diarrhoea, IBS with diarrhoea, and hepatic encephalopathy, sold through both hospitals and pharmacies. Four levers matter more than any others here: what rifamycin SV feedstock costs, how tight Chinese fermentation is and what compliance is costing there, what the euro is doing to European conversion, and how hard hospitals are tendering.
For the rest of 2026, the lean is clearly up. Demand across IBS-D and hepatic encephalopathy keeps broadening, and since hospital tenders set the rhythm of buying, restocking has come in orderly rather than in fits and starts. Underneath all of it, feedstock is getting dearer. Chinese fermentation lines are running close to full. None of that says a sudden jump is coming, but it does say the gains keep landing, quarter after quarter.
So where might it turn? To the upside, a shortage of rifamycin SV, or a compliance shutdown at one of the big Chinese fermentation sites, would tighten supply almost overnight. To the downside, faster generic competition or a pile-up of export stock would drain the momentum and put a lid on FOB offers.
| Region | 2026 Price Range (USD/MT) | Outlook |
| Global Average | 1,030,000 - 1,120,000 | Widening therapy demand, costlier feedstock |
| United States | 1,200,000 - 1,300,000 | Import reliance and regulation, the dearest market |
| China | 895,000 - 970,000 | Fermentation scale anchors the global low |
| Germany | 1,185,000 - 1,285,000 | Euro strength and compliance sustain a premium |
| India | 980,000 - 1,060,000 | Export-oriented capacity holds a firm middle |
US prices reached USD 1,205,000/MT in Q2, about 3.0% above the USD 1,170,000/MT of Q1. Imported feedstock kept climbing, hospital and pharmacy offtake held its ground, and between the two the market had nowhere to go but up.
Why did the price of Rifaximin change in Q2 2026 in United States?
Rifamycin SV just kept getting dearer, which lifted the cost base. Hospitals tendered in their usual disciplined way while IBS-D demand stayed firm, so there was little slack anywhere. USD 1,205,000/MT was simply this quarter's step in a climb that had run all year.
China kept its spot as the low-cost origin, though even there offers firmed to USD 900,000/MT, roughly 2.9% up on USD 875,000/MT. Plants were running flat out, and fermentation inputs had grown more expensive.
Why did the price of Rifaximin change in Q2 2026 in China?
Run that close to full and there is not much spare tonnage to sell. Precursor and energy costs lifted the bottom. Strong export call-offs handled the rest, and offers came to rest around USD 900,000/MT.
Germany came in just shy of the US at USD 1,190,000/MT, about 3.0% over Q1's USD 1,155,000/MT. A firmer euro and heavy compliance costs made the conversion step pricier for European processors.
Why did the price of Rifaximin change in Q2 2026 in Germany?
The stronger euro, plus costlier rifamycin SV imports, put European converters under pressure all quarter. Therapeutic demand across the continent held steady. Together they nudged the average to USD 1,190,000/MT.
India moved up to USD 985,000/MT, roughly 3.1% over the USD 955,000/MT of Q1. Export call-offs picked up, feedstock firmed, and supply tightened accordingly.
Why did the price of Rifaximin change in Q2 2026 in India?
International orders built as the weeks went on, thinning what was around. Imported precursor cost more, edging the bottom higher. USD 985,000/MT is where it came to rest.
The US carried its 2025 run into the new year, printing USD 1,170,000/MT, about 1.3% over Q4. Feedstock pressure and steady demand were still at work.
Why did the price of Rifaximin change in Q1 2026 in United States?
Nothing shifted the direction. Rifamycin SV stayed expensive, demand stayed firm, and the market kept inching up to USD 1,170,000/MT.
China opened 2026 at USD 875,000/MT, up around 1.2% from Q4. Post-holiday output ran near capacity, and early export enquiries put a firmer tone under offers.
Why did the price of Rifaximin change in Q1 2026 in China?
Tight fermentation met steady export interest, and that alone held the market near USD 875,000/MT.
German prices hit USD 1,155,000/MT in Q1, about 1.3% above Q4. Euro-linked conversion costs and firm demand supplied the push.
Why did the price of Rifaximin change in Q1 2026 in Germany?
Feedstock imports and compliance kept break-even high, carrying the quarter to USD 1,155,000/MT.
India started at USD 955,000/MT, roughly 1.1% over Q4, propped up by steady export demand and firmer precursor costs.
Why did the price of Rifaximin change in Q1 2026 in India?
Firm export offtake and dearer feedstock combined to lift the market to USD 955,000/MT.
Rifaximin has gone one way for six quarters straight, and that way is up. From USD 955,000/MT in Q2 2025, the average climbed to USD 975,000/MT, then USD 995,000/MT, then USD 1,010,000/MT in Q1 2026, and USD 1,035,000/MT in Q2, roughly 8.4% over the stretch. Broadening therapy demand and steadily costlier rifamycin SV feedstock account for the whole move.
| Quarter | Price (USD/MT) | QoQ Change | Direction |
| Q2 2026 | 1,035,000 | +2.5% | ↑ Rising |
| Q1 2026 | 1,010,000 | +1.5% | ↑ Rising |
| Q4 2025 | 995,000 | +2.1% | ↑ Rising |
| Q3 2025 | 975,000 | +2.1% | ↑ Rising |
| Q2 2025 | 955,000 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Rifaximin firmed right through 2025. The average started near USD 940,000/MT and ended around USD 995,000/MT, up about 5.9%. Three forces set the direction: wider use across IBS-D and hepatic encephalopathy, orderly hospital tender restocking, and firmer rifamycin SV economics.
The US climbed from about USD 1,090,000/MT early in 2025 to USD 1,155,000/MT by Q4, up roughly 6.0%. Prescribing for IBS-D and hepatic encephalopathy grew steadily and kept demand firm, while imported feedstock cost a bit more each quarter. Demand and feedstock leaned the same way all year.
China went from around USD 815,000/MT to USD 865,000/MT, about 6.1% over the year. Fermentation lines on the east coast ran hard and, importantly, dodged compliance shutdowns. Firmer precursor costs held offers up throughout. Tight capacity against firm export demand was the shape of it.
Germany moved from roughly USD 1,075,000/MT to USD 1,140,000/MT, up about 6.0%. A firm euro and steep compliance costs lifted the conversion economics, and continental therapeutic demand kept offtake steady. Currency and feedstock did most of the pushing.
India firmed from about USD 890,000/MT to USD 945,000/MT, a 6.2% gain and the biggest in percentage terms. Export call-offs built as the year went on, late on in particular, and squeezed availability against pricier precursor. Export strength was the headline.
Expert Market Research: Your Source for Real-Time Rifaximin Price Intelligence
Expert Market Research keeps a constant eye on Rifaximin prices in every region that counts, on both the producing and consuming sides. We go after the cause rather than the headline: rifamycin SV feedstock economics, fermentation capacity and the compliance cycle in China, what the euro is doing to European conversion, and how hospital and pharmacy demand is shifting. The forecasts rest on feedstock economics, trade-flow data, capacity use, and a geopolitical risk read across every market. Reach out to Expert Market Research for Rifaximin pricing, analysis shaped around your needs, and procurement support.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Almost all of it goes into gut and liver medicine: traveller's diarrhoea, IBS with diarrhoea, and hepatic encephalopathy. Hospitals and pharmacies both count, and the IBS-D and hepatic encephalopathy uses are the fastest growing.
As of Q2 2026, the average sat at USD 1,205,000/MT in the US, USD 900,000/MT in China, USD 1,190,000/MT in Germany, and USD 985,000/MT in India. The US costs the most, on import reliance and regulation.
Up. The global average went from about USD 940,000/MT early on to USD 995,000/MT by Q4, roughly 5.9%, on wider demand and costlier rifamycin SV feedstock.
Three things pulled together: IBS-D and hepatic encephalopathy demand kept widening, Chinese fermentation stayed tight, and rifamycin SV feedstock grew dearer, which a strong euro made worse for European converters.
Look for a USD 1,030,000 to 1,120,000/MT band through the rest of 2026, propped up by growing therapy demand and continued feedstock pressure.
The US and Germany sit at the top, on import reliance, regulation, and euro-linked conversion. India holds a firm export-focused middle. China is cheapest, on the back of its large fermentation base.
Every month. For live pricing, reach the Expert Market Research team directly.
Mostly rifamycin SV feedstock, fermentation capacity and compliance, and how fast demand is growing. Currency swings, export licences, and freight can add short-term noise.
China leads on fermentation capacity, India follows, and Italy and France add higher-grade output. Move Chinese capacity or precursor costs and every market tends to feel it inside a quarter or two.
Match contracts to the fermentation and feedstock cycle, weigh fixed price against index-linked supply, and get cover in place before demand firms. The earliest read on the cost base is what rifamycin SV is doing.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.